Pito Chickering

“Hey, good morning, guys, and great quarter, and very much appreciate the comments around 2027. You've become one of the most dominant players in the LDD market in the last few years with you and one other getting exclusivity or winning it together.”

“On the corporate level, my back of the envelope math here is about 150 base points revenue raised. It's a pretty big jump from 4.6 to 6.1. Assuming my math is right.”

“Maybe just kind of staying on the guidance and just to clarify, last quarter you had talked about increasing the operational investments to support customer demand.”

“So the first one is, walk us through the PROS patients that are transferring from HICS onto government and going government before they can go.”

“I'm going to ask the drug compounding question, like revenue guidance rates of 200 to 300 basis, and the implied EPS the back half of the year is a little lighter than the street, despite some good guys like interest.”